Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 3% Dividend Yields

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Benzinga readers can review the latest analyst takes on their favorite stocks by visiting our Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy. Here's a look at the most recent high-yield dividend stock ratings from the most accurate Wall Street analysts, according to Benzinga's Analyst Stock Ratings.

Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.

Pfizer Inc. PFE

• Dividend Yield: 4.50%
• Morgan Stanley analyst Terence Flynn maintained an Equal-Weight rating and cut the price target from $42 to $40 on Aug. 2, 2023. This analyst has an accuracy rate of 65%.
• Wells Fargo analyst Mohit Bansal maintained an Equal-Weight rating and lowered the price target from $50 to $44 on March 17, 2023. This analyst has an accuracy rate of 74%.
• Recent News: The FDA approved Pfizer’s Abrysvo (Respiratory Syncytial Virus Vaccine), the company's bivalent RSV prefusion F (RSVpreF) vaccine, to prevent the infection in infants from birth up to six months of age by active immunization of pregnant individuals at 32 through 36 weeks gestational age.

Amgen Inc. AMGN

• Dividend Yield: 3.32%
• Truist Securities analyst Robyn Karnauskas maintained a Hold rating and cut the price target from $280 to $260 on Feb. 13, 2023. This analyst has an accuracy rate of 64%.
• SVB Leerink analyst David Risinger maintained a Market Perform rating and cut the price target from $282 to $267 on Feb. 2, 2023. This analyst has an accuracy rate of 78%.
• Recent News: Amgen reported strong second-quarter earnings and raised its FY23 outlook.

CVS Health Corporation CVS

• Dividend Yield: 3.59%
• Wells Fargo analyst Stephen Baxter maintained an Equal-Weight rating and cut the price target from $95 to $76 on May 8, 2023. This analyst has an accuracy rate of 61%.
• Bernstein analyst Lance Wilkes maintained a Market Perform rating and cut the price target from $107 to $93 on May 2, 2023. This analyst has an accuracy rate of 66%.
• Recent News: CVS Health reported better-than-expected second-quarter financial results.

Read More: Top 5 Tech Stocks That May Plunge This Quarter